Mupirocin resistance: Clinical implications and potential alternatives for the eradication of mrsa

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 10, 2015, Pages 2681-2692

  Poovelikunnel, T ^a,b   Gethin, G ^c   Humphreys, H ^a,b  

^a BEAUMONT HOSPITAL   (Ireland)

^b ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^c NATIONAL UNIVERSITY OF IRELAND   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

ALCOHOL; BACITRACIN; CHLORHEXIDINE; HYPOCHLORITE SODIUM; LYSOSTAPHIN; OCTENIDINE; OMIGANAN; PROBIOTIC AGENT; PSEUDOMONIC ACID; RETAPAMULIN; SILVER; TEA TREE OIL; ANTIINFECTIVE AGENT; DISINFECTANT AGENT;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIOPHAGE; CLINICAL TRIAL (TOPIC); CONTROLLED CLINICAL TRIAL (TOPIC); DRUG INDICATION; DRUG MECHANISM; DRUG USE; HONEY; HUMAN; META ANALYSIS (TOPIC); METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW (TOPIC); ANIMAL; DRUG EFFECTS; GENETICS; META ANALYSIS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; STAPHYLOCOCCAL INFECTIONS;

ANIMALS; ANTI-BACTERIAL AGENTS; CHLORHEXIDINE; DISINFECTANTS; DRUG RESISTANCE, BACTERIAL; HUMANS; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MUPIROCIN; PREVALENCE; STAPHYLOCOCCAL INFECTIONS;

EID: 84943750921     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv169     Document Type: Article

References (89)

1. de Kraker ME, Davey PG, Grundmann H. Mortality and hospital stay associated with resistant Staphylococcus aureus and Escherichia coli bacteremia: estimating the burden of antibiotic resistance in Europe. PLoS Med 2011; 8: e1001104.
2. Datta R, Huang SS. Risk of infection and death due to methicillinresistant Staphylococcus aureus in long-term carriers. Clin Infect Dis 2008; 47: 176-81.
3. Leigh DA, Joy G. Treatment of familial staphylococcal infection-comparison of mupirocin nasal ointment and chlorhexidine/neomycin (Naseptin) cream in eradication of nasal carriage. J Antimicrob Chemother 1993; 31: 909-17.
4. Walsh TJ, Standiford HC, Reboli AC et al. Randomized double-blinded trial of rifampin with either novobiocin or trimethoprim-sulfamethoxazole against methicillin-resistant Staphylococcus aureus colonization: prevention of antimicrobial resistance and effect of host factors on outcome. Antimicrob Agents Chemother 1993; 37: 1334-42.
5. Harbarth S, Dharan S, Liassine N et al. Randomized, placebo-controlled, double-blind trial to evaluate the efficacy of mupirocin for eradicating carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1999; 43: 1412-6.
6. Safdar N, Bradley EA. The risk of infection after nasal colonization with Staphylococcus aureus. Am J Med 2008; 121: 310-5.
7. Calfee DP, Salgado CD, Milstone AM et al. Strategies to prevent methicillin-resistant Staphylococcus aureus transmission and infection in acute care hospitals: 2014 update. Infect Control Hosp Epidemiol 2014; 35: 772-96.
8. National Clinical Effectiveness Committee. Prevention and Control Methicillin-Resistant Staphylococcus aureus (MRSA), National Clinical Guideline No. 2. 2013. Department of Health, Ireland.
9. Coia JE, Duckworth GJ, Edwards DI et al. Guidelines for the control and prevention of meticillin-resistant Staphylococcus aureus (MRSA) in healthcare facilities. J Hosp Infect 2006; 63 Suppl 1: S1-44.
10. Ammerlaan HSM, Kluytmans JAJW, Wertheim HFL et al. Eradication of methicillin-resistant Staphylococcus aureus carriage: a systematic review. Clin Infect Dis 2009; 48: 922-30.
11. Boelaert JR, Van Landuyt HW, Godard CA et al. Nasal mupirocin ointment decreases the incidence of Staphylococcus aureus bacteraemias in haemodialysis patients. Nephrol Dial Transplant 1993; 8: 235-9.
12. Coates T, Bax R, Coates A. Nasal decolonization of Staphylococcus aureus with mupirocin: strengths, weaknesses and future prospects. J Antimicrob Chemother 2009; 64: 9-15.
13. van Rijen M, Bonten M, Wenzel R et al. Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers. Cochrane Database Syst Rev 2008; issue 4: CD006216.
14. Simor AE, Stuart TL, Louie L et al. Mupirocin-resistant, methicillinresistant Staphylococcus aureus strains in Canadian hospitals. Antimicrob Agents Chemother 2007; 51: 3880-6.
15. Cadilla A, David MZ, Daum RS et al. Association of high-level mupirocin resistance and multidrug-resistant methicillin-resistant Staphylococcus aureus at an academic center in the midwestern United States. J Clin Microbiol 2011; 49: 95-100.
16. Caffrey AR, Quilliam BJ, Laplante KL. Risk factors associated with mupirocin resistance in meticillin-resistant Staphylococcus aureus. J Hosp Infect 2010; 76: 206-10.
17. Choudhury S, Krishnan PU, Ang B. Prevalence of high-level mupirocin resistance among meticillin-resistant Staphylococcus aureus isolates in a tertiary care hospital in Singapore. J Hosp Infect 2012; 82: 56-7.
18. dos Santos KRN, Fonseca LD, Filho PPG. Concise communications. Emergence of high-level mupirocin resistance in methicillin-resistant Staphylococcus aureus isolated from Brazilian university hospitals. Infect Control Hosp Epidemiol 1996; 17: 813-6.
19. Walker ES, Levy F, Shorman M et al. A decline in mupirocin resistance in methicillin-resistant Staphylococcus aureus accompanied administrative control of prescriptions. J Clin Microbiol 2004; 42: 2792-5.
20. Lee AS, Macedo-Vinas M, François P et al. Impact of combined low-level mupirocin and genotypic chlorhexidine resistance on persistentmethicillinresistant Staphylococcus aureus carriage after decolonization therapy: a case-control study. Clin Infect Dis 2011; 52: 1422-30.
21. Patel JB, Gorwitz RJ, Jernigan JA. Mupirocin resistance. Clin Infect Dis 2009; 49: 935-41.
22. Hetem DJ, Bonten MJ. Clinical relevance of mupirocin resistance in Staphylococcus aureus. J Hosp Infect 2013; 85: 249-56.
23. Dupeyron C, Campillo B, Bordes M et al. A clinical trial of mupirocin in the eradication of methicillin-resistant Staphylococcus aureus nasal carriage in a digestive disease unit. J Hosp Infect 2002; 52: 281-7.
24. Mody L, Kauffman CA, McNeil SA et al. Mupirocin-based decolonization of Staphylococcus aureus carriers in residents of 2 long-term care facilities: a randomized, double-blind, placebo-controlled trial. Clin Infect Dis 2003; 37: 1467-74.
25. Walker ES, Vasquez JE, Dula R et al. Mupirocin-resistant, methicillinresistant Staphylococcus aureus: does mupirocin remain effective? Infect Control Hosp Epidemiol 2003; 24: 342-6.
26. Hodgson JE, Curnock SP, Dyke KG et al. Molecular characterization of the gene encoding high-level mupirocin resistance in Staphylococcus aureus J2870. Antimicrob Agents Chemother 1994; 38: 1205-8.
27. Eltringham I. Mupirocin resistance and methicillin-resistant Staphylococcus aureus (MRSA). J Hosp Infect 1997; 35: 1-8.
28. Udo EE, Jacob LE, Mathew B. Genetic analysis of methicillin-resistant Staphylococcus aureus expressing high- and low-level mupirocin resistance. J Med Microbiol 2001; 50: 909-15.
29. Sutherland R, Boon RJ, Griffin KE et al. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. Antimicrob Agents Chemother 1985; 27: 495-8.
30. Seah C, Alexander DC, Louie L et al. MupB, a new high-level mupirocin resistance mechanism in Staphylococcus aureus. Antimicrob Agents Chemother 2012; 56: 1916-20.
31. Swenson JM, Wong B, Simor AE et al. Multicenter study to determine disk diffusion and broth microdilution criteria for prediction of high- and low-level mupirocin resistance in Staphylococcus aureus. J Clin Microbiol 2010; 48: 2469-75.
32. Mongkolrattanothai K, Pumfrey L, Mankin P et al. Acquisition of highlevel mupirocin resistance and its fitness cost among methicillin-resistant Staphylococcus aureus strains with low-level mupirocin resistance. J Clin Microbiol 2009; 47: 4158-60.
33. Han LL, McDougal LK, Gorwitz RJ et al. High frequencies of clindamycin and tetracycline resistance in methicillin-resistant Staphylococcus aureus pulsed-field type USA300 isolates collected at a Boston ambulatory health center. J Clin Microbiol 2007; 45: 1350-2.
34. Bathoorn E, Hetem DJ, Alphenaar J et al. Emergence of high-level mupirocin resistance in coagulase-negative staphylococci associated with increased short-term mupirocin use. J Clin Microbiol 2012; 50: 2947-50.
35. Desroches M, Potier J, Laurent F et al. Prevalence of mupirocin resistance among invasive coagulase-negative staphylococci and methicillin-resistant Staphylococcus aureus (MRSA) in France: emergence of a mupirocin-resistant MRSA clone harbouring mupA. J Antimicrob Chemother 2013; 68: 1714-7.
36. Babu T, Rekasius V, Parada JP et al. Mupirocin resistance among methicillin-resistant Staphylococcus aureus-colonized patients at admission to a tertiary care medical center. J Clin Microbiol 2009; 47: 2279-80.
37. Jones JC, Rogers TJ, Brookmeyer P et al. Mupirocin resistance in patients colonized with methicillin-resistant Staphylococcus aureus in a surgical intensive care unit. Clin Infect Dis 2007; 45: 541-7.
38. Vivoni AM, Santos KRN, de-Oliveira MP et al. Mupirocin for controlling methicillin-resistant Staphylococcus aureus: lessons from a decade of use at a university hospital. Infect Control Hosp Epidemiol 2005; 26: 662-7.
39. Miller MA, Dascal A, Portnoy J et al. Development of mupirocin resistance among methicillin-resistant Staphylococcus aureus after widespread use of nasal mupirocin ointment. Infect Control Hosp Epidemiol 1996; 17: 811-3.
40. Annigeri R, Conly J, Vas S et al. Emergence of mupirocin-resistant Staphylococcus aureus in chronic peritoneal dialysis patients using mupirocin prophylaxis to prevent exit-site infection. Perit Dial Int 2001; 21: 554-9.
41. Liu Q-Z, Wu Q, Zhang Y-B et al. Prevalence of clinical meticillin-resistant Staphylococcus aureus (MRSA) with high-level mupirocin resistance in Shanghai and Wenzhou, China. Int J Antimicrob Agents 2010; 35: 114-8.
42. Park S-H, Kim S-Y, Lee J-H et al. Community-genotype strains of methicillin-resistant Staphylococcus aureus with high-level mupirocin resistance in a neonatal intensive care unit. Early Hum Dev 2013; 89: 661-5.
43. McDanel JS, Murphy CR, Diekema DJ et al. Chlorhexidine and mupirocin susceptibilities of methicillin-resistant Staphylococcus aureus from colonized nursing home residents. Antimicrob Agents Chemother 2013; 57: 552-8.
44. Wang JT, Sheng WH, Wang JL et al. Longitudinal analysis of chlorhexidine susceptibilities of nosocomial methicillin-resistant Staphylococcus aureus isolates at a teaching hospital in Taiwan. J Antimicrob Chemother 2008; 62: 514-7.
45. Hetem DJ, Vogely HC, Severs TT et al. Acquisition of high-level mupirocin resistance in CoNS following nasal decolonization with mupirocin. J Antimicrob Chemother 2015; 70: 1182-4.
46. Longtin J, Seah C, Siebert K et al. Distribution of antiseptic resistance genes qacA, qacB, and smr in methicillin-resistant Staphylococcus aureus isolated in Toronto, Canada, from 2005 to 2009. Antimicrob Agents Chemother 2011; 55: 2999-3001.
47. McDonnell G, Russell AD. Antiseptics and disinfectants: activity, action, and resistance. Clin Microbiol Rev 1999; 12: 147-79.
48. Maki DG, Ringer M, Alvarado CJ. Prospective randomised trial of povidone-iodine, alcohol, and chlorhexidine for prevention of infection associated with central venous and arterial catheters. Lancet 1991; 338: 339-43.
49. Noguchi N, Hase M, Kitta M et al. Antiseptic susceptibility and distribution of antiseptic-resistance genes in methicillin-resistant Staphylococcus aureus. FEMS Microbiol Lett 1999; 172: 247-53.
50. Mayer S, Boos M, Beyer A et al. Distribution of the antiseptic resistance genes qacA, qacB and qacC in 497 methicillin-resistant and -susceptible European isolates of Staphylococcus aureus. J Antimicrob Chemother 2001; 47: 896-7.
51. Lee H, Lim H, Bae IK et al. Coexistence of mupirocin and antiseptic resistance in methicillin-resistant Staphylococcus aureus isolates from Korea. Diagn Microbiol Infect Dis 2013; 75: 308-12.
52. Fritz SA, Hogan PG, Camins BC et al. Mupirocin and chlorhexidine resistance in Staphylococcus aureus in patients with community-onset skin and soft tissue infections. Antimicrob Agents Chemother 2013; 57: 559-68.
53. Vali L, Davies SE, Lai LL et al. Frequency of biocide resistance genes, antibiotic resistance and the effect of chlorhexidine exposure on clinical methicillin-resistant Staphylococcus aureus isolates. J Antimicrob Chemother 2008; 61: 524-32.
54. Zakrzewska-Bode A, Muytjens HL, Liem KD et al. Mupirocin resistance in coagulase-negative staphylococci, after topical prophylaxis for the reduction of colonization of central venous catheters. J Hosp Infect 1995; 31: 189-93.
55. Torvaldsen S, Roberts C, Riley TV. The continuing evolution of methicillin-resistant Staphylococcus aureus in Western Australia. Infect Control Hosp Epidemiol 1999; 20: 133-5.
56. Huang SS, Septimus E, Kleinman K et al. Targeted versus universal decolonization to prevent ICU infection. N Engl J Med 2013; 368: 2255-65.
57. Derde LG, Dautzenberg MD, Bonten MM. Chlorhexidine body washing to control antimicrobial-resistant bacteria in intensive care units: a systematic review. Intensive Care Med 2012; 38: 931-9.
58. Climo MW, Yokoe DS, Warren DK et al. Effect of daily chlorhexidine bathing on hospital-acquired infection. N Engl J Med 2013; 368: 533-42.
59. Milstone AM, Elward A, Song X et al. Daily chlorhexidine bathing to reduce bacteraemia in critically ill children: a multicentre, clusterrandomised, crossover trial. Lancet 2013; 381: 1099-106.
60. O'Grady S, Hirji Z, Pejcic-Karapetrovic B et al. A double-blind, randomized, controlled trial of topical polysporin triple compound versus topical mupirocin for the eradication of colonization with methicillin-resistant Staphylococcus aureus in a complex continuing care population. Can J Infect Dis Med Microbiol 2009; 20: e49-55.
61. Kaiser M, Gil J, Treu R et al. An in vitro analysis of the effects of various topical antimicrobial agents on methicillin-resistant and methicillinsensitive strains of Staphylococcus aureus. Ostomy Wound Manage 2014; 60: 18-28.
62. Saravolatz LD, Pawlak J, Saravolatz SN et al. In vitro activity of retapamulin against Staphylococcus aureus resistant to various antimicrobial agents. Antimicrob Agents Chemother 2013; 57: 4547-50.
63. Tanus T, Scangarella-Oman NE, Dalessandro M et al. A randomized, double-blind, comparative study to assess the safety and efficacy of topical retapamulin ointment 1% versus oral linezolid in the treatment of secondarily infected traumatic lesions and impetigo due to methicillin-resistant Staphylococcus aureus. Adv Skin Wound Care 2014; 27: 548-59.
64. Rohr U, Mueller C, Wilhelm M et al. Methicillin-resistant Staphylococcus aureus whole-body decolonization among hospitalized patients with variable site colonization by using mupirocin in combination with octenidine dihydrochloride. J Hosp Infect 2003; 54: 305-9.
65. Hamson C, Bignardi GE. MRSA decolonization with Prontoderm compared with chlorhexidine and mupirocin. J Hosp Infect 2010; 75: 142-3.
66. Steed LL, Costello J, Lohia S et al. Reduction of nasal Staphylococcus aureus carriage in health care professionals by treatment with a nonantibiotic, alcohol-based nasal antiseptic. Am J Infect Control 2014; 42: 841-6.
67. Liu C, Bayer A, Cosgrove SE et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillinresistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52: e18-55.
68. Fritz SA, Camins BC, Eisenstein KA et al. Effectiveness of measures to eradicate Staphylococcus aureus carriage in patients with communityassociated skin and soft-tissue infections: a randomized trial. Infect Control Hosp Epidemiol 2011; 32: 872-80.
69. Kokai-Kun JF, Walsh SM, Chanturiya T et al. Lysostaphin cream eradicates Staphylococcus aureus nasal colonization in a cotton rat model. Antimicrob Agents Chemother 2003; 47: 1589-97.
70. LaPlante KL. In vitro activity of lysostaphin, mupirocin, and tea tree oil against clinical methicillin-resistant Staphylococcus aureus. Diagn Microbiol Infect Dis 2007; 57: 413-8.
71. McConeghy KW, Mikolich DJ, LaPlante KL. Agents for the decolonization of methicillin-resistant Staphylococcus aureus. Pharmacotherapy 2009; 29: 263-80.
72. Natarajan S, Williamson D, Grey J et al. Healing of an MRSAcolonized, hydroxyurea-induced leg ulcer with honey. J Dermatalog Treat 2001; 12: 33-6.
73. Mayer A, Slezak V, Takac P et al. Treatment of non-healing leg ulcers with honeydew honey. J Tissue Viability 2014; 23: 94-7.
74. Nikpour M, Shirvani MA, Azadbakht M et al. The effect of honey gel on abdominal wound healing in cesarean section: a triple blind randomized clinical trial. Oman Med J 2014; 29: 255-9.
75. Alam F, Islam MA, Gan SH et al. Honey: a potential therapeutic agent for managing diabetic wounds. Evid Based Complement Alternat Med 2014; 2014: 169130.
76. Gethin G, Cowman S. Bacteriological changes in sloughy venous leg ulcers treated with manuka honey or hydrogel: an RCT. J Wound Care 2008; 17: 241.
77. Maeda Y, Loughrey A, Earle JAP et al. Antibacterial activity of honey against community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA). Complement Ther Clin Pract 2008; 14: 77-82.
78. Blaser G, Santos K, Bode U et al. Effect of medical honey on wounds colonised or infected with MRSA. J Wound Care 2007; 16: 325-8.
79. Sherlock O, Dolan A, Athman R et al. Comparison of the antimicrobial activity of ulmo honey from Chile and manuka honey against methicillinresistant Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa. BMC Complement Altern Med 2010; 10: 47.
80. Edmondson M, Newall N, Carville K et al. Uncontrolled, open-label, pilot study of tea tree (Melaleuca alternifolia) oil solution in the decolonisation of methicillin-resistant Staphylococcus aureus positive wounds and its influence on wound healing. Int Wound J 2011; 8: 375-84.
81. Dryden MS, Dailly S, Crouch M. A randomized, controlled trial of tea tree topical preparations versus a standard topical regimen for the clearance of MRSA colonization. J Hosp Infect 2004; 56: 283-6.
82. Blackwood B, Thompson G, McMullan R et al. Tea tree oil (5%) body wash versus standard care (Johnson's Baby Softwash) to prevent colonization with methicillin-resistant Staphylococcus aureus in critically ill adults: a randomized controlled trial. J Antimicrob Chemother 2013; 68: 1193-9.
83. Sikorska H, Smoragiewicz W. Role of probiotics in the prevention and treatment of meticillin-resistant Staphylococcus aureus infections. Int J Antimicrob Agents 2013; 42: 475-81.
84. Durai R, Ng PCH, Hoque H. Methicillin-resistant Staphylococcus aureus: an update. AORN J 2010; 91: 599-609.
85. Miedzybrodzki R, Fortuna W, Weber-Dabrowska B et al. Phage therapy of staphylococcal infections (including MRSA) may be less expensive than antibiotic treatment. Postepy higieny i medycyny doswiadczalnej (Online) 2007; 61: 461-5.
86. Pastagia M, Euler C, Chahales P et al. A novel chimeric lysin shows superiority to mupirocin for skin decolonization of methicillin-resistant and -sensitive Staphylococcus aureus strains. Antimicrob Agents Chemother 2011; 55: 738-44.
87. Vipra AA, Desai SN, Roy P et al. Antistaphylococcal activity of bacteriophage derived chimeric protein P128. BMC Microbiol 2012; 12: 41.
88. Mann NH. The potential of phages to prevent MRSA infections. Res Microbiol 2008; 159: 400-5.
89. ECDC/EMA. The Bacterial Challenge: Time to React. 2009. Stockholm, EMEA/576176/2009.